AACR Annual Meeting | Conference

In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit

April 7th 2024

Fifty-seven percent of drugs granted accelerated approval for a cancer indication failed to show clinical benefit in confirmatory studies.

Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence

April 7th 2024

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

April 21st 2023

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

April 19th 2023

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

Dr Skoulidis on the Implications of the POSEIDON Trial of Tremelimumab Plus Durvalumab in NSCLC

April 18th 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the clinical implications for data from the combination of tremelimumab plus durvalumab and chemotherapy in metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

April 18th 2023

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

Molecular Analysis Needed to Guide Further Study of Olaparib Plus Ceralasertib in Pediatric Advanced Cancers

April 18th 2023

The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.

Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations

April 18th 2023

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Dr Desai on the Efficacy of Divarasib Plus Cetuximab in KRAS G12C–Mutant CRC

April 18th 2023

Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.

Exome Sequencing Is A Feasible Way to Execute CDCT1 Genetic Condition Screening

April 18th 2023

Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.

Dr Bryant on Utilizing Nivolumab With SOC in Grade Group 5 Prostate Cancer

April 18th 2023

John Michael "JM" Bryant, MD, discusses the combination of nivolumab with standard of care in the management of patients with prostate cancer, detailing the results of the interim analysis of the phase 2 trial.

HECTOR Deep Learning Model Shows Predictability for Distant Recurrence Risk in Endometrial Cancer

April 18th 2023

A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.

Divarasib Plus Cetuximab Demonstrates Promising Clinical Activity and Manageable Safety in KRAS G12C–Mutant CRC

April 18th 2023

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

Awareness of the HPV-Cancer Connection, Vaccine Rates Are Lagging

April 18th 2023

Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.

Dr Suvannasankha on the Safety/Efficacy of REGN5459 in R/R Multiple Myeloma

April 18th 2023

Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.

IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC

April 18th 2023

The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.

Lifirafenib/Mirdametinib Combination Is Safe and Tolerable in Advanced/Refractory Solid Tumors

April 18th 2023

Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.

Novel KRAS G12C Inhibitor Shows Early Signs of Efficacy Across Solid Tumors, Pretreated NSCLC

April 17th 2023

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.